Today: 29 June 2026
Browse Category

NASDAQ:SMMT 19 October 2025 - 1 May 2026

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK stock ticks up after Summit cancer-trial tie-up — what investors watch next

GSK shares rose about 0.4% in early London trading after Summit Therapeutics announced a clinical trial collaboration to test ivonescimab with GSK’s experimental B7-H3 cancer drug. Patient dosing is expected to begin in mid-2026. GSK will report full-year results on Feb. 4. Senior managers recently acquired small amounts of GSK shares through company plans.
14 January 2026
···
Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics stock tumbles as FDA filing for ivonescimab hits tape, GSK trial tie-up follows

Summit Therapeutics shares fell 11% to $17.46 Monday after announcing a U.S. FDA biologics license application for its lung cancer drug ivonescimab. The company also disclosed a clinical trial collaboration with GSK to test a combination regimen in solid tumors. Investors are watching for the FDA’s next procedural step and updates from the J.P. Morgan Healthcare Conference.
12 January 2026
·
Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Biggest Stock Losers Today in the U.S. (Dec. 10, 2025): DYN, SLM, KTB, WAY and More Slide as Fed Decision Looms

Dyne Therapeutics shares fell 16.9% to $18.44 after announcing a $300 million stock offering. SLM Corp dropped 15%, Kontoor Brands slid 9.5%, and Waystar Holding lost 8.4%. Major indexes were little changed as investors awaited the Federal Reserve’s interest-rate decision. The U.S. 10-year Treasury yield hovered near 4.19%.
10 December 2025
···········
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics shares traded at $17–18 on December 9, 2025, near the low end of their 52-week range of $15.55 to $36.91. The company’s lung cancer drug ivonescimab recently outperformed Keytruda in a limited trial, drawing attention but also regulatory questions. Summit granted inducement stock options to new hires on December 5. The company’s market cap stands near $13–14 billion.
9 December 2025
·
Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics (SMMT) Skyrockets on Cancer Breakthrough – Key Facts & Outlook

Summit Therapeutics’ stock closed at $20.99 on Oct. 17, up 16% in the past month and 14% year-to-date, with a market cap near $15.6 billion. On Oct. 19, Summit reported Phase 3 trial data showing its cancer drug ivonescimab plus chemo cut lung cancer progression or death risk by 40% versus a standard treatment. The company is expanding trials into colorectal cancer and other tumor types. Q3 earnings and further data updates are expected today.
20 October 2025
·
Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics (SMMT) Stock Soars on Cancer Breakthrough – Can the Biotech’s Rally Hold?

Summit Therapeutics reported positive Phase 3 results for its cancer drug ivonescimab on Oct. 19, reducing disease progression risk by 40% in a key lung cancer trial. Shares closed at $20.99 on Oct. 17, down 4.5% that day but up 14% year-to-date. The company’s market cap stands near $15.6 billion after a 1,770% three-year surge. Summit will report Q3 earnings and present new data at ESMO on Oct. 20.
19 October 2025
·

Stock Market Today

  • Singular Health Group Applies for Quotation of Additional ASX Shares
    June 28, 2026, 8:02 PM EDT. Singular Health Group Ltd has applied for the quotation of 2,571,222 new ordinary fully paid shares on the Australian Securities Exchange (ASX). This move aims to expand the company's market presence and increase liquidity. The application signifies the firm's intent to raise capital or satisfy existing commitments through share issuance. Investors will monitor the impact on share supply and potential dilution. The announcement reflects Singular Health's ongoing efforts to support its growth and operational strategies.

Latest articles

Trump-era loan caps could open door for private lenders in grad school market

Trump-era loan caps could open door for private lenders in grad school market

29 June 2026
July 1 federal loan caps slash Grad PLUS access, forcing many graduate and professional students to seek private loans; Sallie Mae projects up to 70% origination growth over several years, while SoFi reports record student-loan volume—investors now face a real-time test of how much demand shifts to private lenders as federal limits hit.
IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

IREN Limited (NASDAQ:IREN) slides as Warriors badge faces AI revenue test

29 June 2026
IREN Limited (NASDAQ:IREN) plunged 21.3% to $47.21 over five straight down days despite announcing a record $50M+ annual Warriors jersey deal, as investors focused on the company’s not fully contracted $4.4B target ARR and high short interest at 19.74% of float, with Friday’s close near the lowest analyst target.
Go toTop